All Chiesi articles
-
Article
The future of pharma R&D leadership
People, not platforms, will define the next era of innovation, explain Chiesi’s Executive VP of R&D Diego Ardigò and Nick Petschek, EMEA Managing Director at Kotter.
-
NewsPharma's sustainability push continues as Merck signs renewable energy deal
The German pharma company’s agreement for its South Korea sites is the latest green initiative to be unveiled by the industry.
-
NewsChiesi completes expansion of French metered dose inhaler facility
The enlarged La Chaussée-Saint-Victor site will serve as a manufacturing hub for the biopharma company.
-
NewsUnderstanding European regulatory requirements for low-GWP propellant transition
The paper explores recent guidance by the EMA and aims to help companies ensure their developments are efficient and effective for the forthcoming transition.
-
NewsNICE recommends new Fabry disease treatment
Recommendation of Elfabrio® (pegunigalsidase alfa) means patients with Fabry disease in England will be able to access a new treatment option.
-
NewsEnzyme replacement therapy for alpha-mannosidosis gets FDA approval
The first and only enzyme replacement therapy approved for alpha-mannosidosis in the US has been cleared for adult and paediatric patients.